Obesity, insulin resistance, and type 2 diabetes are all known to increase the risk of dementia, largely due to their role in driving inflammation, vascular damage, and other long-term stressors on the brain
Your Freya Meds physician operates independently, but you can request that your treatment records be shared with your primary care provider
Clinical studies have shown that once-weekly injections of our modern medical drugs can lead to significant improvements in blood sugar levels and weight loss
Reasons: Available immediately Best efficacy among approved options (22.5%) Best tolerability (lowest nausea) Lower cost than Semaglutide Consider Semaglutide if: Insurance covers Wegovy but not Zepbound You prioritize longest safety record Waiting for Retatrutide rarely makes sense: 2+ year delay in treatment Tirzepatide delivers excellent results NOW Conclusion The evolution from single to dual to triple agonist represents remarkable progress: The efficacy progression: Semaglutide (single): 14.9% average weight loss Tirzepatide (dual): 22.5% average weight loss (+51% vs Semaglutide) Retatrutide (triple): 28.7% average weight loss (+93% vs Semaglutide) The mechanism progression: Semaglutide: GLP-1 only Tirzepatide: GLP-1 + GIP Retatrutide: GLP-1 + GIP + Glucagon The tolerability comparison: Semaglutide: 6.9% discontinuation (best retention) Tirzepatide: 6.2% discontinuation (best GI tolerability) Retatrutide: 18.2% discontinuation (highest) The availability reality: Semaglutide & Tirzepatide: FDA-approved, available today Retatrutide: Investigational, not until 2027-2028 For most patients in 2026: Tirzepatide represents the best optionsuperior efficacy (22.5%), excellent tolerability (lowest nausea), lower cost, and immediate availability
This is why moderate, balanced approaches that support optimal function rather than complete inhibition may offer better long-term outcomes
